Health Catalyst (HCAT)
NASDAQ:HCAT
Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$1.32
$0.34(4.94%)
At close: 4:00 PM EST
$1.32
$0.34(4.94%)
Day’s Range― - ―
52-Week Range$0.96 - $5.06
Previous CloseN/A
Volume315.36K
Average Volume (3M)753.40K
Market Cap
$92.72M
Enterprise Value$216.82M
Total Cash (Recent Filing)$95.73M
Total Debt (Recent Filing)$171.24M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 12, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding73,586,180
10 Day Avg. Volume653,978
30 Day Avg. Volume753,401
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap2.34
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda15.06
Forecast
1Y Price Target
$2.17Price Target Upside64.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.14
Revenue Forecast (FY)$282.02M
Bulls Say, Bears Say
Bulls Say
Asset MonetizationAnalyst maintains a BUY rating, citing potential shareholder value from divesting attractive app-layer assets or pursuing a full-company sale given the CEO's experience with successful exits.
Operational Efficiency And Growth FocusStreamlined leadership, emphasis on internal utilization and planned investments in India are expected to improve operational efficiency and support more profitable growth.
Recurring Revenue StrengthApplications such as VitalWare deliver strong customer usage and recurring revenue, making them appealing candidates for monetization or licensing to boost cash generation.
Bears Say
Guidance And Near-term Financial PressureNear-term sales and adjusted EBITDA guidance trailing Street estimates, together with the absence of full-year guidance, signals potential short-term financial pressure and higher forecasting uncertainty.
Platform Migration RiskMigration from the legacy DOS platform to the Ignite platform is triggering down-selling and some customer attrition, creating execution risk during the transition.
Strategic Review And Leadership TransitionOngoing strategic and operational review tied to the CEO transition limits near-term actionable initiatives and increases uncertainty about the company's direction.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $5.06 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $92.72M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is May 12, 2026 which is in 19 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on Mar 12, 2026. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.094 by -$0.014.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is 0.02.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 73,586,180 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.08 in its last earnings report, missing expectations of $0.094. Following the earnings report the stock price went down -26.257%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.17 (64.14% Upside)
$2.17 (64.14% Upside)
Blogger Sentiment
Bullish
HCAT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 643.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.62%
12-Months-Change
Fundamentals
Return on Equity
-54.67%
Trailing 12-Months
Asset Growth
-41.48%
Trailing 12-Months
Company Description
Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
HCAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed constructive operational progress — margin expansion, strong adjusted EBITDA growth (59% YoY), 7% technology revenue growth, improved cost discipline, and strategic leadership actions to simplify the commercial story. However, these positives are tempered by material near-term risks: a large $110.2M GAAP impairment, quarterly revenue decline, professional services weakness, and significant DOS-to-Ignite migration headwinds (~$12.5M confirmed churn and ~$52.0M at risk, incl. $35.0M data infrastructure). Management is investing to address migrations and future AI-enabled opportunities but withheld full-year guidance pending strategic review. Overall, the call reflects operational improvement underpinned by meaningful execution risks and financial uncertainty.View all HCAT earnings summariesHCAT Stock 12 Month Forecast
Average Price Target
$2.17
▲(64.14% Upside)
Technical Analysis
HealthStream
―
OptimizeRx
―
Evolent Health
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
7.72% Insiders
14.29% Mutual Funds
2.76% Other Institutional Investors
64.71% Public Companies and
Individual Investors